Patent · US Active

Topically administered strontium-containing complexes for treating pain, pruritis and inflammation

US9333185B2 · kind B2 · utility

5Cited by
2References
18Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMar 15, 2013
Grant dateMay 10, 2016
Priority date
Expiry dateMar 15, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P29/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.